

**UN TRAIN PEUT
EN CACHER
UN AUTRE**



Présentée par : Dr EL HACHEM Georges
Modérateur : Dr SALENGRO Emmanuel,
Service de Cardiologie,
CHI Villeneuve Saint Georges





CAS CLINIQUE



FACTEURS DE RISQUE CARDIOVASCULAIRES

- Mr C. S agé de 60 ans, consulte en février 2022 pour bilan cardiovasculaire
- Diabète type II diagnostiqué en novembre 2021 (HbA1C = 10.7%)
- Surpoids (IMC = 27 kg/m²)
- Tabagisme sevré depuis 20 ans (35 Paquets/année)



SYMPTOMATOLOGIE/EXAMEN CLINIQUE

- Asymptomatique, relativement sédentaire
- Examen Clinique sans particularités



BILAN PARACLINIQUE

- ECG : rythme sinusal 88/minute, axe normal, QRS fins, absence de troubles de repolarization ou de conduction
- LDL = 1.25 g/l
- Echocardiographie : normale
- Epreuve d'effort : 135 W, 82% de la FMT, negative.
- Score calcique coronaire = 452





ECHOGRAPHIE SOUS DOBUTAMINE

nce
-96bd-c295e14fc290

14.04.2022 12:45:05
12 dérivation standard

ECG de base

jour
bre
ment
guête
eur de L
vga.

FC 76 bpm RR 792 ms
P 102 ms
PR 151 ms
Axe P 36° QRS 71 ms
Axe QRS -12° QT 371 ms
Axe T 8° QTcB 417 ms

Rapport non confirmé

Indication
Remarque



25 mm/s, 10 mm/mV

AT-102 C2 1.2 © (1080 008158)

Séquentiel

CHV, Cardiologie - Imprimé sur 14.04.2022 12:45:14

EPB 40 Hz, CA 50Hz

Page 1 / 1


DRU 408

N° séjour
Chambre
Traitement
N° requête
Émetteur de L.
Prot. requ.

FC 155 bpm
Axe P 90°
Axe QRS 88°
Axe T 117°
RR 388 ms
P 99 ms
PR 120 ms
QRS 110 ms
QT 257 ms
QTcB 413 ms

Rapport non confirmé


Indication
Remarque



ESMOCARDIS 100mg


FC	108 bpm	RR	555 ms
		P	110 ms
		PR	142 ms
Axe P	57°	QRS	88 ms
Axe QRS	-16°	QT	364 ms
Axe T	42°	QTcB	489 ms


Rapport non confirmé







CORONAROGRAPHIE A J1













cora



Pa
90

Pd
82

FFR
0.92

00:54 FFR 0.92

FFR 0.92

<Vaisseau> <Étape> <Médicament>

1/1 09:54:22

Navigation icons: back, forward, zoom in, zoom out, left arrow, right arrow.



Patient

Direct

Réviser

Archive

▶ Direct



QUEL EST VOTRE DIAGNOSTIC?

ATTITUDE THERAPEUTIQUE?

EXAMENS A REALISER?

QUEL TEST D'ISCHEMIE POUR LE SUIVI?



SPASME CORONAIRE INDUIT PAR LA DOBUTAMINE



TRAITEMENT DE SORTIE

KARDEGIC 75 mg

ATORVASTATINE 40 mg

VERAPAMIL LP 240 mg





TEST DE PROVOCATION DU SPASME A J30

- Test au Méthylergométrine (Méthergin®)
- Réalisé après 48 heures de washout thérapeutique
- Injection intraveineuse lente de 0.4 mg de methylergometrine (2 ampoules de Méthergin)
- Négatif cliniquement, électriquement et angiographiquement

METHERGIN







TRINITRINE

Table 1 Recapitulation of literature case reports on dobutamine-induced ST-elevation myocardial infarct (STEMI) or coronary spasm (CS)

Author	Age	Symptoms, h/o CAD or CS	Risk factors	Dob.	Atropine/beta-blocker	ST elev	WMA	CAD or NOCAD	Outcome
Cohen A <i>Lancet</i> 1995 ¹⁶	48M	CAD(PCI), CS	N/A	40	Yes/no	Inf+lat At peak	Inf	NOCAD	Resolution with SL nitroglycerin
Mathew J <i>Lancet</i> 1995 ¹⁷	69F (AA)	Exertional CP	N/A	40	Yes/no	Inf+ant at peak	Inf	NOCAD	Resolution with SL nitroglycerin
Deligonul U <i>Clin Cardiol</i> 1996 ¹⁸	35M	Resting CP	Smoker FH HLP	40	No/no	Inf+lat at peak	NA	NOCAD: RCA plaques LAD 20%	Resolution with SL nitroglycerin
Shaheen J <i>Am Heart J</i> 1996 ¹⁹	49M	Inf STEMI, NOCAD	Smoker HLP	40	Yes/no	Inf +V1 at peak	NA	NOCAD: 40%–50% LAD 30%–40% RCA	VF, defibrillation, propranolol for VF
Yamagishi H <i>Jpn Circ J</i> 1998 ²⁰	55F Jpn	Exertional+resting CP	No, h/o breast K	20	No/no	Lat+ant	None	Normal arteries, spasm LCx with dobut	Spontaneous resolution 16 min after termination test
Roffi M <i>Heart</i> 2000 ²¹	58M	CAD (PCI) exertional+resting CP	HLP, ex- smoker	5–20	No/no	Inf+ant, NSVT	None	NOCAD: 50% D1 40% LAD	Resolution with nasal nitroglycerin
Varga A <i>Am J Med</i> 2000 ⁹	55M	CAD, CABGx4, exertional CP	N/A	5	No/no	V3-6 ST depress	New postlat akinesis	Autopsy: no acute MI	Metoprolol+nitrates TdP/VF 9 min into recovery, death
Alvarez L <i>Rev Esp Cardiol</i> 2002 ²²	37M	Resting CP	Smoker EtOH	40	Yes/propranolol	ST elev	Yes	NOCAD	Resolution with IV nitrates
Ferreira LD <i>Rev Port Cardiol</i> 2004 ²³	F	Exertional CP	N/A		N/A	ST elev		Normal arteries	
Jiamsripong P. <i>JASE</i> 2007 ⁸	62M	Pre-op knee surgery	DM HTN HLP	40	Yes/no	12' into recovery	Apical	CAD: 95% LAD	At 12': VT, VF, defib resolution with SL nitroglycerin
Ioannides M <i>Int J Cardiol</i> 2008 ²⁴	45M	Exertional epigastric pain	Obesity DM	40	No/no	Ant ST elev+NSVT/ MI	Ant+lat	NOCAD	Intravenous nitrates, thrombolysis for refractory CS
Fineschi <i>Eur J Echocardiogr</i> 2011 ²⁵	59M	Resting CP	HLP	40	Yes/metoprolol	Ant+lat 10' after βb	Anteroseptal	NOCAD: <50% pLAD	Resolution with SL nitroglycerin
	54M	Exertional, atypical CP	None	40	Yes/propranolol	Inf 3' after βb	Inf+lat	NOCAD: <60% RCA	Emergent Cath, IC nitrates
	65F	h/o CAD resting CP	HTN DM	40	Yes/propranolol	Inf 5' after βb	Inf+lat	NOCAD: 25% LAD+LCx	Resolution with SL nitroglycerin
Burgos-Rosado PR. <i>Arq Bras Cardiol</i> 2014 ²⁶	55M	NA	Obesity HTN, DM	30	No/metoprolol	Inf+ant no chest pain	Yes	NOCAD	Abundant PVCs
Martinez AM <i>Int J Cardiol</i> 2015 ¹⁰	78M	Resting CP	HTN, LBBB	40	Yes/esmolol	Inf, 10' after βb	No	NOCAD: ecstatic LCx	Resolution with SL nitroglycerin
Poorzand H <i>J Cardiothorac Med</i> 2016 ²⁷	42F	Exertional CP	None	30	No/no	Inf+ant at peak	Yes	NOCAD	Resolution with SL nitroglycerin
Fernandes M <i>J Cardiol Curr Res</i> 2017 ²⁸	79F	Pre-op knee surgery	N None	40	No/no	Inf+ant during recovery	None	NOCAD: plaques LAD	No CP, dyspnoea+hypoTN
Rekik S <i>J Electrocardiol</i> 2009 ²⁹	54M	Exertional+resting CP	None	15	No/no	Inf +V4-6 ST-elev (10 mm)	NA	NOCAD: normal arteries	Intravenous nitrates
Cabani E <i>J Cardiovasc Med</i> 2009 ³⁰	80F	Resting CP	HTN	40	No/metoprolol 3 mg intravenous	Inf ST-elev 30' after βb	Inf WMA	NOCAD	Resolution with SL nitroglycerin

AA, African-American; ant, anterior; βb, beta-blocker; CABG, coronary artery bypass graft; CAD, coronary artery disease; Cath, catheterisation; CP, chest pain; defib, defibrillation; depress, depression; DM, diabetes mellitus; Dob., dobutamine; F, female; FH, familial history of CAD; HPL, hyperlipidaemia; HTN, hypertension; hypoTN, hypotension; IC, intracoronary; inf, inferior; IV, intravenous; Jpn, Japanese; LAD, left anterior descending artery; lat, lateral; LCx, left circumflex artery; M, male; N/A, not available; NOCAD, non-occlusive coronary artery disease; NSVT, non-sustained VT; PCI, percutaneous coronary intervention; Pre-op, pre-operative; PVCs, premature ventricular complexes; RCA, right coronary artery; SL, sublingual; ST-elev, ST-elevation; TdP, torsades de pointes; VF, ventricular fibrillation; VT, ventricular tachycardia; WMA, wall motion abnormality.



PHYSIOPATHOLOGIE

- Dobutamine active les récepteurs β_1
- Dobutamine active les récepteurs β_2
- Dobutamine active les récepteurs α_1 adrénergiques
- **Stimulation inotrope et chronotrope → augmentation des besoins myocardiques en oxygène → augmentation débit coronaire (régulé par la libération de N.O par l'endothelium)**
- Dobutamine induit une Vasoconstriction paradoxale si athérosclérose coronaire.

MERCI